The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Epithelial Ovarian Cancer: A Review of Current Management
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
HEINTZ, A., ODICINO, F., MAISONNEUVE, P., QUINN, M., BENEDET, J., CREASMAN, W., NGAN, H., PECORELLI, S., & BELLER, U. (2006) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(06)60033-7 · Cited by 1,277
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.
Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., & Abraham, G. N. (1993) · PubMed · Cited by 1,084
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
JACOBS, I., ORAM, D., FAIRBANKS, J., TURNER, J., FROST, C., & GRUDZINSKAS, J. G. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb02448.x · Cited by 962
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
van der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321002 · Cited by 705
Trimbos, J. B., Vergote, I., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.113 · Cited by 674
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 663
Vergote, I., De Brabanter, J., Fyles, A., Bertelsen, K., Einhorn, N., Sevelda, P., Gore, M. E., Kærn, J., Verrelst, H., Sjövall, K., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03590-x · Cited by 623
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.106 · Cited by 601
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., Miller, A., Park, R., & Major, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221501 · Cited by 583
van der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199507000-00012 · Cited by 578
Hoskins, W. J., Bundy, B. N., Thigpen, J. T., & Omura, G. A. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90100-w · Cited by 544
Whittemore, A. S., Harris, R., Itnyre, J., Halpern, J., & the Collaborative Ovarian Cancer Group (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116426 · Cited by 525
Chou, T.-C., Motzer, R. J., Tong, Y., & Bosl, G. J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1517 · Cited by 524
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
American Society of Clinical Oncology educational book
Perry, M. C. (2003) · Medical Entomology and Zoology · Cited by 471
Markman, M., Liu, P. Y., Wilczynski, S., Monk, B., Copeland, L. J., Alvarez, R. D., Jiang, C., & Alberts, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.013 · Cited by 447
Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women
Rodriguez, C. (2001) · JAMA · doi:10.1001/jama.285.11.1460 · Cited by 424
Rose, P. G., Blessing, J. A., Mayer, A. R., & Homesley, H. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.405 · Cited by 386
Freedland, S. J., Aronson, W. J., Kane, C. J., Presti, J. C., Amling, C. L., Elashoff, D., & Terris, M. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.181 · Cited by 384
Vergote, I., De Wever, I., Tjalma, W., Van Gramberen, M., Decloedt, J., & van Dam, P. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5213 · Cited by 382
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
Rustin, G. J. S., Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I., et al. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh081 · Cited by 378
Self-citationRisk of cancer after use of fertility drugs with in-vitro fertilisation
Venn, A., Watson, L., Bruinsma, F., Giles, G., & Healy, D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05203-4 · Cited by 371
Jacobs, I., Davies, A. P., Bridges, J., Stabile, I., Fay, T., Lower, A., Grudzinskas, J. G., & Oram, D. (1993) · BMJ · doi:10.1136/bmj.306.6884.1030 · Cited by 360
Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M. M., Pyle, L., Johnston, S. R. D., Ahern, R., Smith, I. E., & Gore, M. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1004 · Cited by 338
Epithelial Ovarian Cancer Risk Among Women With Polycystic Ovary Syndrome
SCHILDKRAUT, J. (1996) · Obstetrics & Gynecology · doi:10.1016/0029-7844(96)00226-8 · Cited by 337
Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment
Hess, V., A'Hern, R., Nasiri, N., King, D. M., Blake, P. R., Barton, D. P. J., Shepherd, J. H., Ind, T., Bridges, J., Harrington, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.078 · Cited by 333
Alberts, D. S., Green, S., Hannigan, E. V., O’Toole, R. V., Stock-Novack, D., Anderson, P., Surwit, E. A., Malvlya, V. K., Nahhas, W. A., & Jolles, C. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.706 · Cited by 317
Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters, G. J., Bergman, A. M., van Haperen, V. W. T. R., Veerman, G., Kuiper, C. M., & Braakhuis, B. J. M. (1995) · PubMed · Cited by 312
ICON1 (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.125 · Cited by 287
Rustin, G. J. S., Nelstrop, A. E., Tuxen, M. K., & Lambert, H. E. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010602 · Cited by 283
Self-citationOmura, G., Blessing, J. A., Ehrlich, C. E., Miller, A., Yordan, E., Creasman, W. T., & Homesley, H. D. (1986) · Cancer · doi:10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j · Cited by 278
Management of ovarian cancer: referral to a multidisciplinary team matters
Junor, E., Hole, D., & Gillis, C. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.307 · Cited by 275
CA125 antigen levels in obstetric and gynecologic patients.
Niloff, J. M., KNAPP, R. C., Schaetzl, E., Reynolds, C., & Bast, R. C. (1984) · PubMed · Cited by 271
Kurtz, A. B., Tsimikas, J. V., Tempany, C. M. C., Hamper, U. M., Arger, P. H., Bree, R. L., Wechsler, R. J., Francis, I. R., Kuhlman, J. E., Siegelman, E. S., et al. (1999) · Radiology · doi:10.1148/radiology.212.1.r99jl3619 · Cited by 267
Eisenhauer, E. A., Vermorken, J. B., & van Glabbeke, M. (1997) · Annals of Oncology · doi:10.1023/a:1008240421028 · Cited by 265
Whittemore, A. S., Harris, R., & ltnyre, J. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116429 · Cited by 264
Schilder, J. M., Thompson, A. M., DePriest, P. D., Ueland, F. R., Cibull, M. L., Kryscio, R. J., Modesitt, S. C., Lu, K. H., Geisler, J. P., Higgins, R. V., et al. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6805 · Cited by 263
Blackledge, G., Lawton, F., Redman, C., & Kelly, K. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.132 · Cited by 255
Vasey, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1562 · Cited by 245
Purdie, D., Green, A., Bain, C., Siskind, V., Ward, B., Hacker, N., Quinn, M., Wright, G., Russell, P., & Susil, B. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620606 · Cited by 241
Intraperitoneal antineoplastic drug delivery: rationale and results
Markman, M. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01074-x · Cited by 239
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]
Vergote, I. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1534 · Cited by 239
Advanced Ovarian Cancer Trialists' Group, Aabo, K., Adams, M., Adnitt, P., Alberts, D., Athanazziou, A., Barley, V, Bell, D., Bianchi, U., Bolis, G., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.710 · Cited by 234
Junor, E. J., Hole, D. J., McNulty, L., Mason, M., & Young, J. (1999) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1999.tb08137.x · Cited by 222
Hatch, K. D., Beecham, J. B., Blessing, J. A., & Creasman, W. T. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<269::aid-cncr2820680209>3.0.co;2-o · Cited by 220
Ness, R. B. (2000) · American Journal of Epidemiology · doi:10.1093/aje/152.3.233 · Cited by 217
McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M. L., Ball, H., Berek, J. S., & Woodward, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1589 · Cited by 213
A prospective study of reproductive factors and risk of epithelial ovarian cancer
Hankinson, S. E., Colditz, G. A., Hunter, D. J., Willett, W. C., Stampfer, M. J., ROSNER, B. A., Hennekens, C. H., & Speizer, F. E. (1995) · Cancer · Cited by 201
Why did p53 gene therapy fail in ovarian cancer?
Zeimet, A. G., & Marth, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01139-2 · Cited by 199
A Case-Control Study of Oral Contraceptive Use and Invasive Epithelial Ovarian Cancer
Rosenberg, L., Palmer, J. R., Zauber, A. G., Warshauer, M. E., Lewis, J. L., Strom, B. L., Harlap, S., & Shapiro, S. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117055 · Cited by 195
(1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1668 · Cited by 193
Markman, M., Reichman, B., Hakes, T., Jones, W., Lewis, J. L., Rubin, S., Almadrones, L., & Hoskins, W. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.10.1801 · Cited by 191
Cousins, S. E., Tempest, E., & Feuer, D. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002764.pub2 · Cited by 190
Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis
Garg, P. (1998) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(98)00139-2 · Cited by 182
Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings
Rubin, S. (1999) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(98)00334-2 · Cited by 182
Heintz, A. P. M., Odicino, F., Maisonneuve, P., Beller, U., Benedet, J. L., Creasman, W. T., Ngan, H. Y. S., & Pecorelli, S. (2003) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(03)90118-4 · Cited by 163
Hakes, T. B., Chalas, E., Hoskins, W. J., Jones, W. B., Markman, M., Rubin, S. C., Chapman, D., Almadrones, L., & Lewis, J. L. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90305-3 · Cited by 162
Pelvic inflammatory disease and the risk of epithelial ovarian cancer.
Risch, H. A., & Howe, G. R. (1995) · PubMed · Cited by 162
Hu, L., Hofmann, J., Zaloudek, C., Ferrara, N., Hamilton, T., & Jaffe, R. B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64467-7 · Cited by 161
Dietary factors and the risk of epithelial ovarian cancer.
Vecchia, C. L., Decarli, A., Negri, E., et al. (1987) · PubMed · Cited by 156
Grab, D., Flock, F., Stöhr, I., Nüssle, K., Rieber, A., Fenchel, S., Brambs, H., Reske, S. N., & Kreienberg, R. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5768 · Cited by 148
Cantù, M. G., Buda, A. A., Parma, G., Rossi, R., Floriani, I., Bonazzi, C. M., Dell’Anna, T., Torri, V., & Colombo, N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1232 · Cited by 147
Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk
Hogg, R. J., & Friedlander, M. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.179 · Cited by 145
Gadducci, A., Carnino, F., Chiara, S., Brunetti, I. M., Tanganelli, L., Romanini, A., Bruzzone, M., & Conte, P. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5677 · Cited by 140
Endometrial and ovarian cancer and oral contraceptives - findings in a large cohort study
Vessey, M. P., & Painter, R. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.260 · Cited by 137
Clinical potential of proteomics in the diagnosis of ovarian cancer
Ardekani, A. M., Liotta, L. A., & Petricoin, E. F. (2002) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2.4.312 · Cited by 131
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
Tay, E. H. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)01977-4 · Cited by 124
Evaluation of response: new and standard criteria
Therasse, P. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf649 · Cited by 121
Lambert, H. E., Rustin, G. J. S., Gregory, W. M., & Nelstrop, A. E. (1997) · Annals of Oncology · doi:10.1023/a:1008256431090 · Cited by 119
Self-citationPiccart, M. J., Floquet, A., Scarfone, G., Willemse, P. H. B., Emerich, J., Vergote, I. B., Giurgea, L., Coens, C., Awada, A. H., & Vermorken, J. B. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13360.x · Cited by 119
Wagner, U. A. G., Köhler, S., Reinartz, S., Giffels, P., Huober, J., Renke, K., Schlebusch, H., Biersack, H., Möbus, V. J., Kreienberg, R., et al. (2001) · PubMed · Cited by 116
Tamoxifen for relapse of ovarian cancer
Williams, C., Simera, I., & Bryant, A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001034.pub2 · Cited by 108
Tropé, C., Kærn, J., Högberg, T., Abeler, V. M., Hagen, B., Kristensen, G. B., Onsrud, M., Pettersen, E. O., Rosenberg, P., Sandvei, R., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008399414923 · Cited by 108
Young, R. C., Brady, M. F., Nieberg, R. K., Long, H. J., Mayer, A. R., Lentz, S. S., Hurteau, J. A., & Alberts, D. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.154 · Cited by 106
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò, L., Spinella, F., Salani, D., et al. (2003) · PubMed · Cited by 104
Epenetos, A. A., Hird, V., Lambert, H. E., Mason, P., & Coulter, C. (2000) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2000.99510.x · Cited by 103
The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer
van der Burg, M. E. L., Lammes, F. B., & Verweij, J. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057754 · Cited by 103
Nagele, F. (1995) · Obstetrics and Gynecology · doi:10.1016/0029-7844(95)00126-c · Cited by 100
ASSOCIATION OF OBESITY AND OVARIAN CANCER IN A CASE-CONTROL STUDY
Farrow, D. C., Weiss, N. S., Lyon, J. L., & Daling, J. R. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115249 · Cited by 90
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
van der Burg, M. E. L., de Wit, R., van Putten, W. L. J., Logmans, A., Kruit, W. H. J., Stoter, G., & Verweij, J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600002 · Cited by 87
Bolis, G., Scarfone, G., Giardina, G., Villa, A., Mangili, G., Melpignano, M., Presti, M., Tateo, S., Franchi, M. P., & Parazzini, F. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6151 · Cited by 86
Bergfeldt, K., Rydh, B., Granath, F., Grönberg, H., Thalib, L., Adami, H., & Hall, P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11023-3 · Cited by 79
Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
Sewell, J. M., Macleod, K. G., Ritchie, A., Smyth, J. F., & Langdon, S. P. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600058 · Cited by 79
Gadducci, A., Baicchi, U., Marrai, R., Ferdeghini, M., BIANCHI, R., & Facchini, V. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0025 · Cited by 59
Cited by
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
Multicellular spheroids in ovarian cancer metastases: Biology and pathology
Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.032 · Cited by 412
Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313
Metadata
- Authors
- Guppy, A. E., Nathan, P. D., & Rustin, G. J. S.
- Venue
- Clinical Oncology
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 17
- Issue
- 6
- Pages
- 399-411
- ISSN
- 0936-6555 (ISSN-L)
- OpenAlex
- W2034034974
- Cited by
- 311
- References
- 106
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.